molsidomine has been researched along with Arrhythmia in 7 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of our research was to compare molsidomine, SIN-1, SIN-1A, and lidocaine influence on arrhythmias and hemodynamic parameters in 2 experimental models in rats." | 3.85 | New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology. ( Krzemiński, TF; Mitręga, KA; Porc, M; Żorniak, M, 2017) |
| "Allopurinol-treated hearts had significantly decreased nerve growth factor expression, which was substantially increased after coadministration of 3-morpholinosydnonimine." | 1.37 | Differential effects of NADPH oxidase and xanthine oxidase inhibition on sympathetic reinnervation in postinfarct rat hearts. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| "Molsidomine protected the treated animals from early (10 min) post-ischaemic ventricular fibrillation (0 of 20 vs 6 of 20, P = 0." | 1.27 | Molsidomine prevents post-ischaemic ventricular fibrillation in dogs. ( Cano, JP; Guillen, JC; Jouve, R; Langlet, F; Puddu, PE; Rolland, PH; Serradimigni, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shan, Y | 1 |
| Wang, D | 1 |
| Li, R | 1 |
| Huang, C | 1 |
| Żorniak, M | 1 |
| Mitręga, KA | 1 |
| Porc, M | 1 |
| Krzemiński, TF | 1 |
| Lee, TM | 1 |
| Chen, CC | 1 |
| Hsu, YJ | 1 |
| Kuz'ko, NV | 1 |
| Barnes, CS | 1 |
| Coker, SJ | 2 |
| Aitchison, KA | 1 |
| Cano, JP | 1 |
| Guillen, JC | 1 |
| Jouve, R | 1 |
| Langlet, F | 1 |
| Puddu, PE | 1 |
| Rolland, PH | 1 |
| Serradimigni, A | 1 |
7 other studies available for molsidomine and Arrhythmia
| Article | Year |
|---|---|
Molsidomine Attenuates Ventricular Electrical Remodeling and Arrhythmogenesis in Rats With Chronic β-Adrenergic Receptor Activation Through the NO/cGMP/PKG Pathway.
Topics: Adrenergic beta-Agonists; Animals; Arrhythmias, Cardiac; Cells, Cultured; Cyclic GMP; Cyclic GMP-Dep | 2016 |
New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
Topics: Animals; Anti-Asthmatic Agents; Arrhythmias, Cardiac; Creatine Kinase; Disease Models, Animal; Hemod | 2017 |
Differential effects of NADPH oxidase and xanthine oxidase inhibition on sympathetic reinnervation in postinfarct rat hearts.
Topics: Acetophenones; Allopurinol; Animals; Arrhythmias, Cardiac; Coronary Vessels; Ethidium; Male; Molsido | 2011 |
[Treatment with sidnonimine derivatives of chronic ischemic heart disease patients].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Chronic Disease; Coronary Disease; Drug Evaluation; Female; H | 1984 |
Failure of nitric oxide donors to alter arrhythmias induced by acute myocardial ischaemia or reperfusion in anaesthetized rats.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cyclic AMP; Cyclic GMP; Hemodynam | 1995 |
Potential interactions between iloprost and SIN-1 on platelet aggregation and myocardial infarct size in vivo.
Topics: Animals; Arrhythmias, Cardiac; Creatine Kinase; Drug Synergism; Electrocardiography; Hemodynamics; I | 1999 |
Molsidomine prevents post-ischaemic ventricular fibrillation in dogs.
Topics: Adenosine Diphosphate; Animals; Arrhythmias, Cardiac; Cardiac Output; Coronary Disease; Dogs; Electr | 1986 |